Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12...2122232425262728293031...858859»
  • ||||||||||  Review, Journal:  Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. (Pubmed Central) -  Oct 21, 2024   
    Here I highlight evidence establishing the efficacy of GLP-1-based medicines, while discussing data that inform safety, focusing on muscle strength, bone density and fractures, exercise capacity, gastrointestinal motility, retained gastric contents and anesthesia, pancreatic and biliary tract disorders, and the risk of cancer. Rapid progress in development of highly efficacious GLP-1 medicines, and anticipated differentiation of newer agents in subsets of metabolic disorders, will provide greater opportunities for use of personalized medicine approaches to improve the health of people living with cardiometabolic disorders.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal, Real-world evidence, Real-world:  Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study. (Pubmed Central) -  Oct 21, 2024   
    Rapid progress in development of highly efficacious GLP-1 medicines, and anticipated differentiation of newer agents in subsets of metabolic disorders, will provide greater opportunities for use of personalized medicine approaches to improve the health of people living with cardiometabolic disorders. Most patients with migraine were prescribed erenumab 70
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    Journal:  Intralesional Talimogene Laherparepvec Immunotherapy for Melanoma: A Case Study. (Pubmed Central) -  Oct 21, 2024   
    Safety considerations and further investigations into potential interactions with other immunotherapies are warranted to optimize treatment strategies and ensure patient well-being. As oncolytic virotherapy continues to evolve, T-VEC stands as a potential option for the treatment of advanced melanoma.
  • ||||||||||  namilumab (IZN-101) / Amgen, Izana Biosci, Roivant
    MT203. Advanced Cardiac Life Support for the Perioperative Setting: PeRLS (Non-CME) (Exhibit Hall - ASA Resource Center Mini Theater) -  Oct 19, 2024 - Abstract #ASA2024ASA_6885;    
    DESCRIPTION Find out how PeRLS can save time and better prepare care teams for the crises they're more likely to encounter in the OR. Designed as an alternative to ACLS, PeRLS goes beyond the basic skills anesthesia professoinals use every day to emphasize critical thinking in high-impact scenarios.
  • ||||||||||  ivabradine / Generic mfg.
    Clinical, Retrospective data, Journal:  Efficacy and Safety of Ivabradine for Patients With Acute (Pubmed Central) -  Oct 19, 2024   
    Ivabradine can reduce heart rate and BNP and NT-pro BNP levels and elevate EF values and 6-min walk distance data significantly in acute heart failure patients. It also exhibits a stable safety profile, with similar risks of all-cause mortality, cardiogenic mortality, incidents of readmission, and major adverse cardiovascular effects compared with those of the control group.
  • ||||||||||  Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen, Rituxan (rituximab) / Roche
    Review, Journal:  CD19: a promising target for systemic sclerosis. (Pubmed Central) -  Oct 18, 2024   
    This work is crucial for the broader clinical application of this novel biologic and improving outcomes for patients with severe asthma. Uplizna
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Trial completion date, Trial primary completion date:  TEPEZZA (clinicaltrials.gov) -  Oct 18, 2024   
    P4,  N=313, Active, not recruiting, 
    Uplizna Trial completion date: Oct 2025 --> Apr 2026 | Trial primary completion date: Oct 2025 --> Apr 2026
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Enrollment change:  NATIENS: Optimal Management and Mechanisms of SJS/TEN (clinicaltrials.gov) -  Oct 17, 2024   
    P3,  N=150, Recruiting, 
    Trial completion date: Jan 2031 --> Apr 2031 | Trial primary completion date: Jun 2027 --> Sep 2027 N=267 --> 150
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Bone complications of cancer treatment. (Pubmed Central) -  Oct 17, 2024   
    (1)Cancer treatment-related osteonecrosis is primarily linked to the use of radiation therapy and certain chemicals, such as bisphosphonates, denosumab, antiangiogenic agents, and immunomodulators...These treatment-related bone disorders have a considerable adverse impact on the prognosis of cancer patients. Hence, it is imperative to prioritize the bone health of patients undergoing cancer treatment and give it further attention.
  • ||||||||||  MORAb-028 / Eisai, Amgen
    Journal:  Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential. (Pubmed Central) -  Oct 17, 2024   
    Research suggests numerous indications, from axon regeneration and cancer, would benefit from a small molecule inhibitor of non-muscle myosin II, a molecular motor that regulates the actin cytoskeleton. Current chemical probe options are very limited and lack sufficient safety for in vivo studies, which we show is primarily due to potent inhibition of cardiac myosin II.Rational design that focused on improving target selectivity over the pan-myosin II inhibitor, blebbistatin, led to the identification of MT-228, a small molecule inhibitor with a wide therapeutic window.High-resolution structure of MT-228 bound to myosin II reveals that selectivity results from a different positioning compared to blebbistatin and an important sequence difference between cardiac and non-muscle myosin II in the inhibitor binding pocket.A single administration of MT-228 shows long-lasting efficacy in animal models of stimulant use disorder, a current unmet and rapidly escalating need with no FDA-approved treatments.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Retrospective data, Journal, IO biomarker:  Clinical analysis of 7 cases of acute B cell lymphoblastic leukemia with t (17;19) (q21-22;p13)/TCF3-HLF fusion (Pubmed Central) -  Oct 17, 2024   
    Two patients did not achieve remission even after two rounds of induction chemotherapy, with one achieving complete remission after treatment with blinatumomab immunotherapy...Five patients died, while two patients survived with sustained complete remission. TCF3-HLF-positive B-ALL is rare and has a high relapse rate and poor prognosis.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Journal:  Modeling lung adenocarcinoma metastases using patient-derived organoids. (Pubmed Central) -  Oct 17, 2024   
    Investigation of the response of KRASG12C PDOs to sotorasib demonstrates that the model can examine the efficacy of treatments to suppress metastasis and identify mechanisms of drug resistance. Finally, our PDO model cocultured with autologous peripheral blood mononuclear cells can potentially be used to determine the optimal immune-priming strategy for individual patients with LUAD.
  • ||||||||||  Orkedia (evocalcet) / Mitsubishi Tanabe, Parsabiv (etelcalcetide) / Amgen
    Journal:  Heterogenous Origins of Calcium Homeostasis Disorders Arising from Five Heterozygous Calcium-Sensing Receptor Variants. (Pubmed Central) -  Oct 16, 2024   
    Palbociclib met prespecified criteria to declare a signal of activity in patients with HNC with CDKN2A alterations, but not in the HP cohort. While the molecular phenotypes exhibited by the five CaSR variants concord with the clinical phenotypes in individuals harboring them, CASR variant-induced calcium homeostasis disorders clearly arise from diverse molecular origins, and the effectiveness of calcimimetics in these disorders could differ depending on the specific variants.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Journal:  The correlation between cellular O-GlcNAcylation and sensitivity to O-GlcNAc inhibitor in colorectal cancer cells. (Pubmed Central) -  Oct 16, 2024   
    Furthermore, we demonstrated that Os exhibited a synergistic relationship with regorafenib (Re)...Finally, we showed that the Os:Re combination suppressed the growth of NCI-H508 tumor spheroids. Overall, our findings highlighted OGTi as a potential anticancer agent that could be used in combination with other molecules to enhance the efficacy while minimizing adverse effects, and identified total cellular O-GlcNAcylation as a potential predictive marker for OGTi sensitivity.
  • ||||||||||  fludrocortisone / Generic mfg., midodrine hydrochloride / Generic mfg., ivabradine / Generic mfg.
    Review, Journal:  Management of Postural Orthostatic Tachycardia Syndrome in Pediatric Patients: A Clinical Review. (Pubmed Central) -  Oct 16, 2024   
    Before adding pharmacotherapeutic interventions, non-pharmacologic interventions such as patient education, avoidance of symptom-triggering environments and medications, dietary fluid and sodium supplementation, exercise, and use of compression garments should be first attempted. Although the body of evidence for the management of POTS is expanding, additional research is needed to determine safe and efficacious dosing and establish clear guidelines for POTS in the pediatric population.